JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Zoonotic babesiosis.

Zoonotic babesiosis has received increased attention recently, due mainly to the interest in tick-borne zoonotic diseases generated by the emergence of Lyme borreliosis and to increased awareness of diagnostic and treatment difficulties associated with co-infection cases. The vast majority of European cases have been caused by Babesia divergens in splenectomised patients, and although rare, this disease is very dangerous, requiring aggressive treatment. The use of atovaquone, a recently developed anti-protozoan agent for human treatment, may be considered in future cases. Most human babesiosis caused by B. microti have occurred in the north-eastern states of the USA and can affect spleen-intact as well as asplenic patients. The majority of infections are subclinical or follow a mild chronic course, but dangerous acute infections can occur in immunocompromised patients. The role of B. microti in apparently unresponsive cases of Lyme borreliosis and treatment of co-infections require further investigation. The zoonotic potential of B. microti in Europe is still unresolved, but the vector competence of Ixodes ricinus for at least some European (and American) strains has been demonstrated.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app